Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal DegenerationGlobeNewsWire • 11/08/21
Here's Why Shares of Moderna, Novavax, and Ocugen Have All Been Extremely Volatile This WeekThe Motley Fool • 11/05/21